As Covid-19 sweeps the globe, a growing number of efforts are underway to quickly research and develop treatments and vaccines. Yet much of the work is disjointed and widespread access to any medical product is uncertain. One idea, suggested by Costa Rican officials, is for the World Health Organization to create a voluntary pool and collect patent rights, regulatory test data, and other information that could be shared for product development. The notion is attracting interest, but Paul Fehlner wants to go a step further. The former global head of intellectual property at Novartis — who now works in a similar role at Axcella Health, but also launched a separate startup — now wants to start a public benefit entity to repurpose generic drugs. The nascent plan is to collect research data, submit whatever looks promising to regulators, and permit existing generic manufacturers to add Covid-19 use to their labels under terms that would require affordable pricing. We spoke with him about his idea. This is an edited version of the conversation.

Pharmalot: What is it you’re trying to do and why?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
    • Interesting position with hydroxychloroquine. Clinicians and patient reports are saying patients testing negative after 2-3 days on HCQ even without an antiviral.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy